DYN
Dyne Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.69
−2.05%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -16.0%
- EBIT
- -21.8%
- EPS
- +13.7%
- Free cash flow
- -37.9%
- Operating cash flow
- -32.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -10.4%
- EPS
- -5.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -38.7%
- EBIT
- -36.1%
- Net income
- -40.6%
- EPS
- -3.0%
- Free cash flow
- -37.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026